Core Viewpoint - Vincerx Pharma, Inc. has terminated its previously signed binding Term Sheet for a reverse merger transaction with Oqory, Inc. and Vivasor, Inc. [1] Group 1: Strategic Alternatives - The board of directors will reassess the Company's strategic alternatives, which may include out-licensing, merger and acquisition opportunities (including reverse mergers), sale of assets and technologies, and winding down operations [2] - The Company had approximately $3.9 million in cash as of February 26, 2025, with an expected cash runway extending through late Q2 2025 [2]

Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, and Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates (ADCs) for the treatment of cancer, today highlighted Phase 1a/1b data for Oqory’s anti-TROP2 ADC, OQY-325 ...

SAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (NASDAQ:VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, and Oqory, Inc., a private biopharmaceutical company dedicated to developing next-generation antibody drug conjugates (ADCs) for the treatment of cancer, today highlighted Phase 1a/1b data for Oqory's anti-TROP2 ADC, OQY-3258, for patients with solid tumors. The companies also provided ...

Core Viewpoint - Vincerx Pharma, Inc. has announced a 1-for-20 reverse stock split of its common stock, effective January 27, 2025, to reduce the number of issued shares and potentially enhance the stock price [1][2]. Summary by Sections Reverse Stock Split Details - The reverse stock split will convert every 20 issued shares into 1 issued share, reducing the total from approximately 44.8 million shares to about 2.2 million shares [2]. - No fractional shares will be issued; stockholders entitled to a fractional share will receive a cash payment instead [2]. - Adjustments will be made to the number of shares underlying outstanding equity awards, warrants, and other agreements [2]. Implementation and Process - Continental Stock Transfer & Trust Company will act as the exchange agent for the reverse stock split [3]. - Registered stockholders will have their positions automatically adjusted, while those with certificate shares will receive instructions from the exchange agent [3]. Company Overview - Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer [5]. - The company's pipeline includes several products in various stages of development, such as VIP943 in Phase 1 and VIP236, which has completed Phase 1 [5]. - Vincerx is headquartered in San Mateo, California, with a research facility in Monheim, Germany [6].

Merger and Strategic Transaction - Vincerx Pharma has entered into a binding term sheet for a proposed merger with Oqory Inc, a clinical-stage company developing ADCs for oncology [1] - Post-merger, Oqory equity holders are expected to own approximately 95% of the combined entity, while Vincerx equity holders will hold about 5% [10] - The transaction includes a minimum fully diluted equity value of $13.66 million for existing Vincerx stockholders and a concurrent offering of at least $20 million in equity securities [10] - Oqory-designated investors will provide interim financing to Vincerx of $1.5 million in two tranches, with $1 million funded immediately and $500,000 to be funded by January 31, 2025 [10] Leadership and Organizational Changes - Dr Ahmed Hamdy has stepped down as CEO but remains Chairman, while Dr Raquel Izumi has taken over as Acting CEO in a consulting capacity [2] - Alexander Seelenberger has stepped down as CFO, with Kevin Hass assuming the role of Acting CFO [2] - Mr Seelenberger will continue to assist the company in a consulting capacity [2] Pipeline and Clinical Development - Oqory’s pipeline includes multiple ADC programs, with two in clinical development and several next-generation ADCs in preclinical stages [4] - OQY-3258, Oqory’s anti-TROP2 ADC, has shown an 83% overall response rate and 100% disease control rate in first-line triple-negative breast cancer [11] - OQY-3258 has completed Phase 1/2 development in over 150 patients with solid tumors and is being evaluated in two Phase 3 studies for breast cancer [11] - Vincerx’s pipeline includes VIP943, a next-generation ADC in Phase 1, VIP236, a small molecule drug conjugate, and enitociclib, a CDK9 inhibitor [5] Financial and Operational Measures - Vincerx is implementing streamlining and cost-control measures, including a workforce reduction, as part of its due diligence and transaction-related work [2] - The merger is subject to customary closing conditions, including due diligence, regulatory approvals, and stockholder approval from both parties [10]

PALO ALTO, Calif., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced plans to implement cost-controls and explore strategic alternatives to support advancing the Phase 1 study of VIP943, the Company’s novel CD123-targeted antibody-drug conjugate (ADC) developed with the Company’s next-generation VersAptx™ platform. “We believe VIP943 is ...

Revenue Generation - The company has not recognized any revenue to date and does not expect to generate revenue in the foreseeable future[84]. Expenses - Research and development expenses decreased by approximately $2.2 million and $13.0 million for the three and nine months ended September 30, 2024, compared to the same periods in 2023[93]. - General and administrative expenses increased by approximately $0.3 million for the three months ended September 30, 2024, but decreased by approximately $1.4 million for the nine months ended September 30, 2024, compared to the same periods in 2023[94]. - The total operating expenses for the three months ended September 30, 2024, were $7.8 million, a decrease of $1.8 million compared to $9.6 million for the same period in 2023[92]. - The net loss for the three months ended September 30, 2024, was $7.8 million, a decrease of $1.2 million compared to a net loss of $9.0 million for the same period in 2023[92]. Licensing and Milestone Payments - The company paid Bayer a $5.0 million upfront license fee under the Bayer License Agreement and will be responsible for significant development and commercial milestone payments[82]. - The company paid Bayer an upfront license fee of $5.0 million and may owe future milestone payments ranging from $110.0 million to $318.0 million per licensed product, potentially exceeding $1.0 billion for successful commercialization of at least five products[101]. Cash and Capital Resources - As of September 30, 2024, the company had approximately $10.1 million in cash, cash equivalents, and marketable securities, and raised $16.9 million in April 2024 through stock sales[102]. - Net cash used in operating activities for the nine months ended September 30, 2024, was approximately $19.9 million, with a net loss of approximately $22.1 million during the same period[113]. - Cash flows from investing activities for the nine months ended September 30, 2024, included $11.5 million in purchases of marketable securities, offset by $4.5 million in sales and maturities[114]. - The company entered into an ATM Agreement allowing for the sale of up to $50.0 million in common stock, with approximately $47.5 million remaining available as of September 30, 2024[115]. - On April 30, 2024, the company closed a public offering raising approximately $14.8 million from the sale of 6.0 million shares of common stock and accompanying warrants[116]. - The company expects to need additional capital prior to the one-year anniversary of its unaudited financial statements due to existing cash resources and anticipated operating losses[109]. - The company anticipates that cash used in operating activities may decrease in the near term due to capital constraints, but could increase again if additional funding is obtained[112]. Risk Management - The company has not been exposed to material risks from interest rate changes or foreign currency fluctuations, as operations are primarily in U.S. dollars[122][123]. - The company is unable to estimate exact operating capital requirements due to various uncertainties in research, development, and commercialization processes[104]. Future Expectations - The company expects operating expenses in 2024 to be comparable to 2023, subject to raising additional capital[100]. - The company intends to prioritize resources towards advancing Phase 1 studies of VIP943 while controlling discretionary spending in other areas[100]. - Interest income decreased to $0.2 million for the three months ended September 30, 2024, from $0.3 million for the same period in 2023[97]. - The change in fair value of warrant liabilities for the three months ended September 30, 2024, was primarily due to an increase in the volatility of the company's common stock[96].

Exhibit 99.1 Vincerx Pharma Reports Third Quarter 2024 Financial Results Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123 antibody-drug conjugate (ADC); additional data expected by early 2025 Completed Phase 1 dose-escalation studies of small molecule drug-conjugate (SMDC), VIP236, and CDK9 inhibitor, enitociclib, and identified the maximum tolerated dose Expected cash runway into early 2025 PALO ALTO, Calif., Nov. 12, 2024 — Vincerx Pharma, Inc. (N ...

Core Viewpoint - Vincerx Pharma, Inc. (VINC) has received a Zacks Rank 2 (Buy) upgrade, indicating a positive trend in earnings estimates which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [3][5]. - Institutional investors utilize earnings estimates to determine the fair value of stocks, leading to buying or selling actions that affect stock prices [3]. Company Performance Indicators - The upgrade reflects an improvement in Vincerx Pharma's underlying business, suggesting that investors may respond positively by driving the stock price higher [4]. - For the fiscal year ending December 2024, Vincerx Pharma is expected to earn -$0.78 per share, representing a 58.7% change from the previous year [7]. - Over the past three months, the Zacks Consensus Estimate for Vincerx Pharma has increased by 38.7%, indicating a positive trend in earnings estimates [7]. Zacks Rank System Overview - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks which have averaged a +25% annual return since 1988 [6]. - The upgrade to Zacks Rank 2 places Vincerx Pharma in the top 20% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [9].

VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1 dose-escalation study, reinforcing the program's potential and validating the VersAptx™ Platform technology Vincerx focusing resources on continued development of VIP943 Expected cash runway into early 2025 Management to host webcast and Q&A today at 5:00 PM EDT to review pipeline and corporate updates, followed by commentary from key opinion leader Dr. M. Yair Levy PALO ALTO, Calif., Oct. 07, 2024 ( ...